The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
Sportschosun (English) on MSN14h
A woman in her 30s with stage 4 colorectal cancer had this warning sign a year agoA woman in her 30s who underwent surgery for stage 4 colon cancer delivered the 'danger signal' she experienced a year ago ...
Pioneering the World's 1st Dark Matter Cancer Immunotherapy UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Cli ...
Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...
Given these findings, a diagnosis of HAC of the colon with metastasis to a mesenteric lymph node was made. We present the case of a young woman with hepatoid adenocarcinoma (HAC) of the colon, which ...
The American people have consistently supported life-saving cancer research. Now the nation’s bedrock source of public funding for biomedical research is under attack.
Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $-0.31. Operator: Greetings, and welcome to the Fulgent ...
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback